Literature DB >> 19234115

A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

Lin Yang1, Jiangang Jiang, Lauren M Drouin, Mavis Agbandje-McKenna, Chunlian Chen, Chunping Qiao, Dongqiuye Pu, Xiaoyun Hu, Da-Zhi Wang, Juan Li, Xiao Xiao.   

Abstract

To engineer gene vectors that target striated muscles after systemic delivery, we constructed a random library of adeno-associated virus (AAV) by shuffling the capsid genes of AAV serotypes 1 to 9, and screened for muscle-targeting capsids by direct in vivo panning after tail vein injection in mice. After 2 rounds of in vivo selection, a capsid gene named M41 was retrieved mainly based on its high frequency in the muscle and low frequency in the liver. Structural analyses revealed that the AAVM41 capsid is a recombinant of AAV1, 6, 7, and 8 with a mosaic capsid surface and a conserved capsid interior. AAVM41 was then subjected to a side-by-side comparison to AAV9, the most robust AAV for systemic heart and muscle gene delivery; to AAV6, a parental AAV with strong muscle tropism. After i.v. delivery of reporter genes, AAVM41 was found more efficient than AAV6 in the heart and muscle, and was similar to AAV9 in the heart but weaker in the muscle. In fact, the myocardium showed the highest gene expression among all tissues tested in mice and hamsters after systemic AAVM41 delivery. However, gene transfer in non-muscle tissues, mainly the liver, was dramatically reduced. AAVM41 was further tested in a genetic cardiomyopathy hamster model and achieved efficient long-term delta-sarcoglycan gene expression and rescue of cardiac functions. Thus, direct in vivo panning of capsid libraries is a simple tool for the de-targeting and retargeting of viral vector tissue tropisms facilitated by acquisition of desirable sequences and properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19234115      PMCID: PMC2656185          DOI: 10.1073/pnas.0813207106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.

Authors:  J Palomeque; E R Chemaly; P Colosi; J A Wellman; S Zhou; F Del Monte; R J Hajjar
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

3.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

4.  Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo.

Authors:  Christina A Pacak; Cathryn S Mah; Bijoy D Thattaliyath; Thomas J Conlon; Melissa A Lewis; Denise E Cloutier; Irene Zolotukhin; Alice F Tarantal; Barry J Byrne
Journal:  Circ Res       Date:  2006-07-27       Impact factor: 17.367

5.  rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Authors:  Paul Gregorevic; James M Allen; Elina Minami; Michael J Blankinship; Miki Haraguchi; Leonard Meuse; Eric Finn; Marvin E Adams; Stanley C Froehner; Charles E Murry; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2006-07-02       Impact factor: 53.440

Review 6.  New approaches in the therapy of cardiomyopathy in muscular dystrophy.

Authors:  Elizabeth M McNally
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

7.  Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

Authors:  Haiyan Jiang; Glenn F Pierce; Margareth C Ozelo; Erich V de Paula; Joseph A Vargas; Peter Smith; Jürg Sommer; Alvin Luk; Catherine S Manno; Katherine A High; Valder R Arruda
Journal:  Mol Ther       Date:  2006-07-05       Impact factor: 11.454

8.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Authors:  Ciaran D Scallan; Haiyan Jiang; Tongyao Liu; Susannah Patarroyo-White; Jurg M Sommer; Shangzhen Zhou; Linda B Couto; Glenn F Pierce
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

9.  Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.

Authors:  Narendra Maheshri; James T Koerber; Brian K Kaspar; David V Schaffer
Journal:  Nat Biotechnol       Date:  2006-01-22       Impact factor: 54.908

10.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Authors:  Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai
Journal:  Mol Ther       Date:  2006-05-19       Impact factor: 11.454

View more
  95 in total

Review 1.  The evolution of heart gene delivery vectors.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Dongsheng Duan
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 2.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 3.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

5.  A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes.

Authors:  Zhenhua Yuan; Chunping Qiao; Peiqi Hu; Juan Li; Xiao Xiao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

6.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

7.  Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.

Authors:  Bo He; Ru-hang Tang; Noah Weisleder; Bin Xiao; Zhenhua Yuan; Chuanxi Cai; Hua Zhu; Peihui Lin; Chunping Qiao; Jianbin Li; Christina Mayer; Juan Li; Jianjie Ma; Xiao Xiao
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 8.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

Review 9.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

Review 10.  Human Cardiac Gene Therapy.

Authors:  Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.